Advertisement
Canada markets closed

  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CAD/USD

    0.7262
    -0.0002 (-0.02%)
     

  • CRUDE OIL

    82.61
    -0.12 (-0.15%)
     

  • Bitcoin CAD

    87,455.76
    +2,665.79 (+3.14%)
     

  • CMC Crypto 200

    1,312.99
    +427.45 (+48.27%)
     

  • GOLD FUTURES

    2,394.30
    -3.70 (-0.15%)
     

  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     

  • 10-Yr Bond

    4.6470
    +0.0620 (+1.35%)
     

  • NASDAQ futures

    17,530.00
    -17.25 (-0.10%)
     

  • VOLATILITY

    18.00
    -0.21 (-1.15%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     

  • CAD/EUR

    0.6822
    +0.0020 (+0.29%)
     

Today's Research Reports on Trending Tickers: Geron and Arrowhead Pharmaceuticals

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / September 17, 2018 / U.S. markets were mixed on Friday, but finished the week in the green, as investors focused on upbeat corporate earnings and positive economic data, instead of a potential trade war. On Thursday, President Donald Trump instructed aides to carry on with $200 billion tariffs against Chinese goods. The Dow Jones Industrial Average climbed 0.03 percent to close at 26,154.67 and is up by 09 percent for the week, while the S&P 500 Index jumped 0.03 percent to close at 2,904.98, surged 1.2 percent for the week. The Nasdaq Composite Index dropped 0.05 percent to close at 8,010.04, gained 1.4 percent for the week.

“Trade wars are certainly a concern, but I don’t know that they’re a one-moment-in-time thing. So far we’ve looked past them, but over the longer term a trade war could be very damaging,” according to Richard Weeks, managing partner at VWG Wealth Management.

“Between high corporate profits, stock buybacks, and muted interest rates, there’s still an underlying bid to the market no matter how you slice it. There are still plenty of things to be concerned about, but there aren’t enough reasons to be too pessimistic,” he added.

RDI Initiates Coverage on:

Geron Corporation
https://rdinvesting.com/news/?ticker=GERN

ADVERTISEMENT

Arrowhead Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=ARWR

Geron's stock moved 3.53% lower Friday, to close the day at $5.46. The stock recorded a trading volume of 7,826,313 shares, which was above its three months average volume of 5,911,476 shares. In the last year, Geron's shares have traded in a range of 1.74 - 6.99. The share price has gained 213.79% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $4.63 is above its 200-day moving average of $3.95. Shares of Geron have gained roughly 37.88 percent in the past month and are up 203.33 percent year-to-date.

Access RDI's Geron Corporation Research Report at:
https://rdinvesting.com/news/?ticker=GERN

On Friday, shares of Arrowhead Pharmaceuticals recorded a trading volume of 1,512,010 shares, which was below the three months average volume of 2,426,830 shares. The stock ended the day 3.16% higher at $18.91. The share price has fallen 15.54% from its 52 week high with a 52 week trading range of 3.01 - 22.39. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $15.85 is above its 200-day moving average of $11.52. Shares of Arrowhead Pharmaceuticals have gained roughly 31.96 percent in the past month and are up 413.86 percent year-to-date.

Access RDI's Arrowhead Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ARWR

Our Actionable Research on Geron Corporation (NASDAQ:GERN) and Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

https://www.accesswire.com/512056/Todays-Research-Reports-on-Trending-Tickers-Geron-and-Arrowhead-Pharmaceuticals